Đang chuẩn bị liên kết để tải về tài liệu:
Visualizing the dynamics of genetic profile in breast cancer treatment: A better way to explain why a drug could be repurposed: A riview

In this work, we further enhance our computational framework for breast cancer drug repurposing by visualizing the prospected dynamic gene expression after the treatment. Practically, the most challenging problem in drug repurposing is to prioritize the list of drugs for further in vivo validation and entering clinical trials. | Journal of military pharmaco-medicine no1-2019 VISUALIZING THE DYNAMICS OF GENETIC PROFILE IN BREAST CANCER TREATMENT: A BETTER WAY TO EXPLAIN WHY A DRUG COULD BE REPURPOSED: A RIVIEW Nguyen Thanh Minh1; Nguyen Thi Kim Tran2; Jake Yue Chen1 SUMMARY In this work, we further enhance our computational framework for breast cancer drug repurposing by visualizing the prospected dynamic gene expression after the treatment. Practically, the most challenging problem in drug repurposing is to prioritize the list of drugs for further in vivo validation and entering clinical trials. In drug repurposing, the possible candidate drugs could be between fifty and several hundreds, depending on different approaches for candidate selection. In contrast, due to the budget and safety constraints, a repurposing clinical trial usually contain only one or a few drugs. In a prior work, we achieved some successes in solving the prioritization problem. However, we were not able to provide detailed and easy to understand explanation on the prospected dynamic changes of the genetic information. The visualization presented in this work would help achieving this task. The complete framework of computing and visualization helps the doctor to select one repurposed strategy: Targeting ACHE gene in breast cancer for in vivo validation with promising result. * Keywords: Breast cancer; Drug; Genetics. INTRODUCTION Drug repurposing (also called drug repositioning) has become one of the most active areas in pharmacology since last decade because this approach could significantly reduce the cost and time to invent a new treatment. Before drug repurposing research became active, it was expected to take about 15 years and $0.8 - $1 billion to invent a new drug [1], due to many tests and clinical trials in order to be commercially approved by American Food and Drug Administration (FDA). It is expected that the failure probability during clinical trials is about 91.4% [2]. Briefly, drug repurposing finds .